Not yet a member?

    Popular Topics
    Search


    Forums
  • Forums
  • Ask a question about:

    Our Supporters
    Syndication
    Subscribe

High Blood Pressure and Anti-Angiogenic Therapy: A Beneficial Side Effect?

October 20, 2009 - 9:59 pm

One of the most common side effects of many different anti-angiogenic agents, which are felt to decrease the tumor’s blood supply, is high blood pressure, also known as hypertension.   The cause of this isn’t really known, but most patients develop some degree of high blood pressure.  What is interesting is that there is growing [...]

8 Comments

Large Trials Completed with Zactima (ZD6474, vandetanib) in Advanced NSCLC

March 14, 2008 - 1:54 pm

   We’ve been following the development of a drug called Zactima (also known as ZD6474, or vandetanib) for over a year as it continues to be studied in lung cancer, and the work continues. As first discussed in my initial post on this agent, this agent actually inhibits BOTH VEGF and EGFR (in fact, the [...]

10 Comments

Thalidomide in Lung Cancer: Answers from Korea

September 21, 2007 - 9:41 pm

To many outside of oncology, thalidomide is primarily known for causing severe birth defects in women who received it in the 1960s as a sedative and treatment for morning sickness. These birth defects, in which babies were born with no arms or legs but with hands and feet directly attached [...]

0 Comments

Vascular Disrupting Agent AS1404/ ASA404/ DMXAA: A Variant on Anti-Angiogenesis

August 23, 2007 - 4:44 pm

First, I want to thank members Jim (dadawg001) and Neil (neilb) for bringing up this topic in the Discussion/Q&A Forum yesterday. Amazingly, yesterday morning I happened to be reviewing slides in my collection on a novel agent and approach that I thought would make a good topic for a post here: the [...]

7 Comments

Axitinib: New Drug with Activity in Lung Cancer

July 1, 2007 - 1:27 pm

A few new agents emerged from the ASCO 2007 meeting as very real potential players in lung cancer. Probably at the lead of that list, in my opinion, was axitinib (AG-013736, now a Pfizer product). Similar to agents like sunitinib and sorafenib, this is an oral agent that blocks a target [...]

8 Comments

COX-2/EGFR Inhibitor Therapy: Hope or Hype?

April 13, 2007 - 5:23 pm

While there have been studies of the COX-2 inhibitor celebrex in combination with chemo for treating NSCLC, the palpable buzz about celebrex in treating lung cancer has been from a trial by my friend Karen Reckamp, formerly at UCLA, now recently moved to City of Hope Cancer Center in nearby Duarte, CA. [...]

2 Comments